Clinical trial NCT04389112: Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions
Official title: Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cutaneous Squamous Cell Carcinoma
Basal Cell Carcinomas
Keywords: Actinic keratosis
mitochondria
metabolism
Lead sponsor: University Hospital, Bordeaux
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé Et de la Recherche Médicale, France
First posted: 2020-05-15
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Skin carcinomas are the most frequent cancers in the world, including basal cell carcinomas and cutaneous squamous cell carcinoma (cSCCs), with more than 60.000 new annual cases in France. Their incidence increases mainly due to ultraviolet (UV) exposure and population ageing. Then from 1994 to 2006, the incidence of cSCC has increased by 300%. CSCCs typically manifests as a spectrum from a precursor actinic keratosis (AK) - possible spontaneous regression at this stage- to in situ cSCC invasive cSCC and finally metastatic cSCC.

Detailed description: Although growing evidence indicates that bioenergetic metabolism plays an important role in the progression of tumorigenesis, little information is available on the contribution of reprogramming of energy metabolism in cancer initiation and how it influences further the bioenergetic behavior of tumors.

By applying a quantitative proteomic approach, the consortium has recently found that specific metabolic modifications precede cSCC.

This study will investigate the role of energy metabolism in malignant transformation of premalignant skin lesions into cSCC, and in cSCC progression, with correlation with clinical characteristics and metastatic outcomes. Using several cutting-edge technologies in human samples, the team will evaluate whether targeting energy metabolism has the potential to be used as curative treatments for cSCC and whether pre-determined metabolic alterations could be exploited as new preventive strategies. These modifications in energy metabolism could be used as prognostic and diagnostic biomarkers.

Eligibility criteria: Inclusion Criteria:

* Every patient with suspected lesion :

  * AK,
  * in situ cSCC,
  * infiltrative cSSC
  * cSCC with recurrent disease
  * cSCC with cutaneous metastases.
* Patients 18 years of age or older,
* Patients with suspected AK or BCC lesions (in situ, infiltrating or metastatic),
* Patient able to sign a consent form,
* Patient affiliated with a Social Security system.

Exclusion Criteria:

* Prior systemic treatment such as checkpoint inhibitors or chemotherapy.
* Patients with cSCC or AK localized on visible zone of the face or folds

Primary outcomes:
measure: Proportion of patients who have a glycolysis profile (proteomic analysis liquid chromatography-mass spectrometry (LC-MS/MS))
timeFrame: Day 1
measure: Proportion of patients who have an oxidative profile (proteomic analysis liquid chromatography-mass spectrometry (LC-MS/MS))
timeFrame: Day 1
Secondary outcomes:
measure: Evaluation of skin differentiation markers
timeFrame: Day 1
measure: Evaluation of cSCC aggressiveness markers
timeFrame: Day 1
measure: Evaluation of skin apoptotic markers
timeFrame: Day 1
measure: Evaluation of mitochondrial metabolism on skin biopsies
timeFrame: Day 1
measure: Evaluation of cancer proliferative features on skin biopsies
timeFrame: Day 1
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Hôpital Saint-André - CHU de Bordeaux
Study officials:
affiliation: University Hospital, Bordeaux
name: Marie BEYLOT-BARRY, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Obre E, Rossignol R. Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. Int J Biochem Cell Biol. 2015 Feb;59:167-81. doi: 10.1016/j.biocel.2014.12.008. Epub 2014 Dec 24.
citation: Hosseini M, Dousset L, Mahfouf W, Serrano-Sanchez M, Redonnet-Vernhet I, Mesli S, Kasraian Z, Obre E, Bonneu M, Claverol S, Vlaski M, Ivanovic Z, Rachidi W, Douki T, Taieb A, Bouzier-Sore AK, Rossignol R, Rezvani HR. Energy Metabolism Rewiring Precedes UVB-Induced Primary Skin Tumor Formation. Cell Rep. 2018 Jun 19;23(12):3621-3634. doi: 10.1016/j.celrep.2018.05.060.
citation: Hosseini M, Dousset L, Michon P, Mahfouf W, Muzotte E, Bergeron V, Bortolotto D, Rossignol R, Moisan F, Taieb A, Bouzier-Sore AK, Rezvani HR. UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis. Oncogenesis. 2019 Sep 24;8(10):52. doi: 10.1038/s41389-019-0161-z.
citation: Mahfouf W, Hosseini M, Muzotte E, Serrano-Sanchez M, Dousset L, Moisan F, Rachidi W, Taieb A, Rudolf J, Rezvani HR. Loss of Epidermal HIF-1alpha Blocks UVB-Induced Tumorigenesis by Affecting DNA Repair Capacity and Oxidative Stress. J Invest Dermatol. 2019 Sep;139(9):2016-2028.e7. doi: 10.1016/j.jid.2019.01.035. Epub 2019 Mar 13.